下载本文档
版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEGSK2110183 hydrochlorideCat. No.: HY-15966ACAS No.: 2070009-64-0分式: CHClFNOS分量: 481.77作靶点: Akt作通路: PI3K/Akt/mTOR储存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性数据体外实验 DMSO : 36 mg/mL (74.72 mM)* means so
2、luble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制备储备液1 mM 2.0757 mL 10.3784 mL 20.7568 mL5 mM 0.4151 mL 2.0757 mL 4.1514 mL10 mM 0.2076 mL 1.0378 mL 2.0757 mL请根据产品在不同溶剂中的溶解度,选择合适的溶剂配制储备液,并请注意储备液的保存式和期限。BIOLOGICAL ACTIVITY物活性 GSK2110183 hydrochloride个服有效的,ATP 竞争性的选择性 pan-Akt 抑制
3、剂,作于Akt1/Akt2/Akt3,Ki 值分别为 0.08/2/2.6 nM。IC50 & Target Akt1 Akt2 Akt3 Akt1 E17K mutant0.08 nM (Ki) 2 nM (Ki) 2.6 nM (Ki) 0.2 nM (IC50)1/3 Master of Small Molecules 您边的抑制剂师www.MedChemEPKG1 PKA PKG1 ROCK0.9 nM (IC50) 1.3 nM (IC50) 4 nM (IC50) 100 nM (IC50)PKC P70S6K RSK1 PKC1210 nM (IC50) 251 nM (IC50
4、) 316 nM (IC50) 430 nM (IC50)PKC510 nM (IC50)体外研究 GSK2110183 is an ATP competitive, time dependant and fully reversible inhibitors of the Akt kinase family.GSK2110183 has a Ki of 0.08, 2 and 2.6 nM against Akt1, Akt2 and Akt3, respectively. GSK2110183 inhibitsthe kinase activity of the E17K Akt 1 mu
5、tant protein in a standard kinase assay with EC50 of 0.2 nM 1.体内研究 Mice bearing BT474 breast tumor xenografts are dosed orally with either vehicle or GSK2110183 at 10, 30 or100 mg/kg daily for 21 days which result in 8, 37 and 61% TGI, respectively. Mice tolerated GSK2110183well, with 1-3% body weig
6、ht loss reported after 5 days of dosing which recover over the course of the study.Other tumor xenograft models which possess an activation of the Akt pathway are explored to furtherdemonstrate compound efficacy. Mice treated with GSK2110183 at 10, 30 and 100 mg/kg result in 23, 37and 97% TGI, respe
7、ctively, of SKOV3 xenografts 1.PROTOCOLKinase Assay 1 The potency of compounds against Akt enzymes is measured. Since GSK2110183 and GSK2141795 arehighly potent inhibitors of the 3 isoforms of Akt, the true potency (Ki) of the inhibitors is initially determined atlow enzyme concentrations (0.1 nM Ak
8、t1, 0.7 nM Akt2, and 0.2 nM Akt3) using a filter binding assay and thenconfirmed with progress curve analysis. In the filter binding assay, a pre-mix of enzyme plus inhibitor isincubated for 1 h and then added to a GSK peptide (Ac-KKGGRARTSSFAEPG-amide) and 33P ATP.Reactions are terminated after 2 h
9、 and the radio labeled Akt peptide product is captured in a phospho-cellulose filter plate. Progress curve analysis utilized continuous real-time fluorescence detection of productformation using the Sox-Akt-tide substrate (Ac-ARKRERAYSF-d-Pro-Sox-Gly-NH2) 1.MCE has not independently confirmed the ac
10、curacy of these methods. They are for reference only.Cell Assay 1 Cell lines are typically grown in RPMI 160 medium containing 10% FBS. Some cell lines are grown in mediaspecified by the vendor. A 3-day proliferation assay using CellTiter-Glo is performed to measure the growthinhibition by the compo
11、unds at 0-30 M. Cell growth is determined relative to untreated (DMSO) controls.EC50s are calculated from inhibition curves using a 4- or 6-parameter fitting algorithm in the Assay Clientapplication 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Anim
12、al Mice 1Administration 1 Tumors are initiated by injecting either cells (SKOV3, CAPAN-2 and HPAC) or a tumor fragments (BT474)subcutaneously into 6-8 week female athymic nude (SKOV3) and SCID (all others) mice. Once tumors reachbetween 120 and 300 mm3, mice are randomized according to tumor volume
13、into groups of n = 7-10 miceper treatment. GSK2110183 (10, 30 or 100 mg/kg daily for 21 days) and GSK2141795 are administered daily2/3 Master of Small Molecules 您边的抑制剂师www.MedChemEat various doses by oral gavage. In combination experiments, GSK1120212 is also administered daily by oralgavage. Tumor
14、volumes and body weight are measured twice weekly, tumor volume is measured withcalipers and calculated.MCE has not independently confirmed the accuracy of these methods. They are for reference only.户使本产品发表的科研献 Theranostics. 2019 Jan 30;9(4):1096-1114. Methods Mol Biol. 2018;1711:351-398.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Dumble M, et al. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PLoS One.2014 J
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 河南省许昌市济源平顶山2021届高三地理第一次质量检测试题
- 两个人合伙台球厅合同范本
- 设备销售及售后合同范本
- 聘用顾问合同范本
- 共享体育用品租赁合同范本
- 2023年卫生院及社区医疗服务项目需求分析报告
- 年度乡镇年度工作规划
- 志愿者年终总结
- 小学三年级数学口算 30以内×1位第81~100篇
- Unit 1 How can I get there?(单元卷)人教PEP版 英语六年级上册
- 《家长开放日》课件
- 管理学原理组织设计
- 青少年运动员培育和梯队建设方案
- 服务器基础与日常运维
- 五子棋课件公开课课件
- 《降水的变化与分布》
- 全国优质课一等奖初中道德与法治人教版八年级上册《以礼待人》课件
- 卫生洁具采购与安装投标方案(技术标)
- 安徽省义务教育阶段实验教学指导手册初中 生物+化学+物理 学分册2023年
- 大林和小林(新版)
- 光伏自发自用项目年用电清单和消纳计算表
评论
0/150
提交评论